41.81
0.33 (0.80%)
| Previous Close | 41.48 |
| Volume | 10,807,236 |
| Price / Sales | 3.88 |
| Price / Book | 7.08 |
| 52 Weeks Range |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Roivant Sciences Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -1.00 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 34.71 | -200,000 | -6,942,000 |
| Aggregate Net Quantity | -200,000 | |||
| Aggregate Net Value ($) | -6,942,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 34.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Officer | 28 Aug 2026 | Automatic sell (-) | 200,000 | 34.71 | 6,942,000 |
| VENKER ERIC | Officer | 28 Aug 2026 | Option execute | 200,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |